Disorder
In chronic pain, we have strong evidence that our pain modulation system is not working well. Instead ofsuppression, the system may be over-sensitized so that even normal sensations trigger pain transmission and suffering. As a result of the pain, patients may also have increased levels of anxiety and depression, decreased quality of life, fear of […]
Testimony
The following written comments were submitted to the Dockets Management Staff (HFA-305) Food and Drug Administration by IFFGD President, Ceciel T. Rooker, in response to Docket No. FDA-2015-D-2479 on October 15, 2019. Thank you for your leadership at the Office of Policy in the Food and Drug Administration (FDA). The International Foundation for Gastrointestinal Disorders (IFFGD) […]
Testimony
On May 11, 2015, Tegan Gaetano took part in and presented the following comments on behalf of IFFGD members at the FDA Patient-Focused Drug Development public meeting on Functional GI Disorders: Good afternoon. My name is Tegan Gaetano. I work for a patient advocacy organization, the International Foundation for Functional Gastrointestinal Disorders, or IFFGD. I […]
Testimony
IFFGD Legislative Successes IFFGD PRESENTS SENATOR BALDWIN WITH 2019 DDNC DISTINGUISHED PUBLIC SERVICE AWARD From introducing multiple statements in the Senate recognizing Gastroparesis Awareness Month to leading a resolution in the House to raise awareness of functional gastrointestinal (GI) and motility disorders, Senator Tammy Baldwin (WI) has been a constant champion for the digestive health community […]
Patients_First_How_FDA_is_Making_Patients_a_Priority.pdf
Report from IFFGD Research Award Winner: Sleep and Gastroesophageal Reflux Disease (GERD) By: Ronnie Fass, MD Chair Division of Gastroenterology and Hepatology; Head of the Esophageal and Swallowing Center, Metro Health Medical Center, Case Western University, Cleveland, OH. Dr. Fass is the recipient of the 2011 IFFGD Research Award for Senior Investigator in Clinical Science. […]